CorMedix (CRMD) Other Accumulated Expenses (2015 - 2025)
CorMedix (CRMD) reported Other Accumulated Expenses of $2.3 million for Q4 2025, up 1749.19% on a YoY basis from $124000.0 in Q4 2024, and up 722.8% sequentially from $278684.0 in Q3 2025.
CorMedix (CRMD) Other Accumulated Expenses (2015 - 2025) Analysis & Trends
CorMedix (CRMD) has 11 years of Other Accumulated Expenses data on file, last reported at $2.3 million in Q4 2025.
- For the quarter ending Q4 2025, Other Accumulated Expenses rose 1749.19% year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2025 stood at $2.3 million (up 1749.19% YoY), and the FY2025 full-year result was $2.3 million, up 1749.19% from the prior year.
- Other Accumulated Expenses climbed to $2.3 million in Q4 2025, from $278684.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $2.3 million in Q4 2025 to a low of $54763.0 in Q3 2023.
- A 5-year average of $242973.4 and a median of $112783.0 in 2021 frame the typical range for Other Accumulated Expenses.
- Peak annual rise in Other Accumulated Expenses reached 1749.19% in 2025, while the deepest fall reached 68.76% in 2025.
- Tracing CRMD's Other Accumulated Expenses over 5 years: stood at $94736.0 in 2021, then slumped by 31.96% to $64456.0 in 2022, then jumped by 127.01% to $146324.0 in 2023, then fell by 15.26% to $124000.0 in 2024, then surged by 1749.19% to $2.3 million in 2025.
- Business Quant data shows CRMD's Other Accumulated Expenses at $2.3 million in Q4 2025, $278684.0 in Q3 2025, and $136298.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn |
| 10 | CorMedix | 5.03 Mn | -150.18 Mn | 107.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.29 Mn |
| Sep 30, 2025 | 278,684.00 |
| Jun 30, 2025 | 136,298.00 |
| Mar 31, 2025 | 87,423.00 |
| Dec 31, 2024 | 124,000.00 |
| Sep 30, 2024 | 191,995.00 |
| Jun 30, 2024 | 436,290.00 |
| Mar 31, 2024 | 226,662.00 |
| Dec 31, 2023 | 146,324.00 |
| Sep 30, 2023 | 54,763.00 |
| Jun 30, 2023 | 111,260.00 |
| Mar 31, 2023 | 55,385.00 |
| Dec 31, 2022 | 64,456.00 |
| Sep 30, 2022 | 83,438.00 |
| Jun 30, 2022 | 84,942.00 |
| Mar 31, 2022 | 89,784.00 |
| Dec 31, 2021 | 94,736.00 |
| Sep 30, 2021 | 67,112.00 |
| Jun 30, 2021 | 118,609.00 |
| Mar 31, 2021 | 114,306.00 |